ArticleBMC cardiovascular disorders2026
Thrombectomy reduces femoral vein valve damage after acute iliofemoral vein thrombosis: a combined retrospective and prospective cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute iliofemoral deep vein thrombosis (IFDVT) often leads to femoral vein valve incompetence and post-thrombotic syndrome (PTS). This study evaluated whether thrombus volume reduction surgery (TVRS) is associated with better valve function preservation compared with simple anticoagulation (SA) in patients with acute IFDVT.
methodsA combined retrospective and prospective cohort study involving 504 patients with acute IFDVT compared TVRS (n = 238) and SA (n = 266). The primary outcome was the femoral vein valve preservation rate at 12 months. Secondary outcomes included PTS incidence and quality of life. Subgroup analysis compared two pharmacomechanical thrombectomy devices: AngioJet and Acostream. Propensity score matching (1:1 nearest neighbor, caliper 0.05), inverse probability of treatment weighting, and E-value sensitivity analysis were employed to address confounding. An exploratory mediation analysis (hypothesis-generating) examined whether valve preservation potentially mediates the association between TVRS and PTS reduction.
resultsThe TVRS group showed a significantly higher valve preservation rate (75.8% vs. 43.9%, P < 0.001) and a lower incidence of moderate-to-severe PTS (13.6% vs. 34.8%, P = 0.002) compared with the SA group. TVRS patients also achieved better quality of life scores with comparable safety profiles. In a pre-specified, exploratory subgroup analysis of patients who underwent PMT with complete ultrasound follow-up data (n = 50 per device), AngioJet appeared to be associated with a higher valve preservation rate compared with Acostream (82% vs. 70%, P = 0.04), although this comparison was underpowered, non-randomized, and should be considered strictly hypothesis-generating.
conclusionsTVRS was associated with improved femoral vein valve preservation, lower PTS incidence, and enhanced quality of life compared with SA. The AngioJet system may be associated with better valve protection than the Acostream system, but this finding is exploratory and requires validation in randomized trials. These observations support the hypothesis that early thrombectomy intervention may be beneficial for long-term venous function, but cannot establish causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.